| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $29,020,684 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG070279 | Cognitive Aging Trajectories in Survivors of Trauma | 000 | 4 | NIH | 3/9/2026 | $125,626 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01DK128022 | Elucidating Molecular Mechanisms Linking Fructose to Cholesterol Metabolism | 000 | 5 | NIH | 12/18/2025 | $148,186 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01HL177045 | Circadian Regulation of Cardiomyocyte Size and Function | 000 | 2 | NIH | 2/10/2026 | $144,909 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | G08LM014412 | DASH-ing to Heart Health: Supporting Low-Income African American Women with an Interactive "Meals that Heal" Resource Book | 000 | 3 | NIH | 12/18/2025 | $254,234 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31AG087618 | Using the gut microbiome to treat disuse atrophy in aging. | 000 | 2 | NIH | 1/14/2026 | $44,495 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL175979 | PPARgamma Coregulators in Rosiglitazone-Induced Cardiovascular Disease | 000 | 2 | NIH | 1/31/2026 | $35,518 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31HL170972 | Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction | 000 | 3 | NIH | 2/25/2026 | $35,530 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T9952106 | Value-Based Medical Student Education Training Program | 02 | 3 | HRSA | 2/9/2026 | $0 |
| | 2026 | 2026 | University of Kentucky Research Foundation, The | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T9952106 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 12/9/2025 | $1,175,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD118715 | Functional Characterization of Genetic Variants in Rare Disease Associated with Shoc2 scaffold | 000 | 2 | NIH | 1/23/2026 | $368,136 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140312 | Targeting Intracellular Cholesterol Distribution: Mechanisms and Therapeutic Strategies for Metabolic dysfunction-associated steatotic liver disease (MASLD) | 000 | 1 | NIH | 3/11/2026 | $707,062 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES033767 | Phthalate-Induced Dysregulation of Prostaglandin and Angiogenic Function During Ovulation in Women | 000 | 5 | NIH | 12/12/2025 | $440,911 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES032396 | A university-community partnership to reduce exposure to disinfection byproducts in Appalachia | 000 | 6 | NIH | 12/11/2025 | $368,566 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK113625 | Contributions of Hepatic and Intestinal Pathways to Cholesterol Excretion | 000 | 9 | NIH | 3/5/2026 | $491,578 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK124626 | Mechanisms for activation of beige adipose tissue in humans | 000 | 5 | NIH | 1/13/2026 | $448,041 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA284532 | Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | 000 | 3 | NIH | 2/27/2026 | $402,968 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA033862 | Examining the Impact of the Twin Epidemics of Methamphetamine and Opioid Use on Overdose, Risky Sex and Treatment Engagement among PWUD in Two Rural Appalachian Cohorts | 000 | 12 | NIH | 1/29/2026 | $482,290 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA063069 | Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study with Pentoxifylline | 000 | 2 | NIH | 3/3/2026 | $612,820 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 001 | 4 | NIH | 2/6/2026 | $67,776 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA062746 | Impact of Cannabis on Opioid Self-Administration: Determining if Cannabis Alters the Drive to Take Opioids in Individuals with Opioid Use Disorder | 000 | 1 | NIH | 2/4/2026 | $647,142 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 000 | 4 | NIH | 1/26/2026 | $610,002 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA060632 | Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study | 000 | 2 | NIH | 3/3/2026 | $621,805 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AI175220 | Chlamydia type III effectors affecting the host actin-based cytoskeleton | 000 | 4 | NIH | 1/30/2026 | $560,781 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084282 | Using the gut microbiome to treat skeletal muscle atrophy | 000 | 2 | NIH | 1/16/2026 | $399,502 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG097476 | RETURN: RECOVERY TO PHYSICALFUNCTION AFTER CRITICAL ILLNESS IN OLDER ADULTS | 000 | 1 | NIH | 1/30/2026 | $382,830 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG093616 | Evaluation of Noninvasive Muscle Imaging Biomarkers for Knee Osteoarthritis in Older Adults | 000 | 1 | NIH | 1/23/2026 | $666,504 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG090534 | Blood-Brain Barrier Dysfunction in Alzheimer’s Disease: New Mechanistic Insights and Therapeutic Strategies | 001 | 2 | NIH | 2/24/2026 | $71,324 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG090534 | Blood-Brain Barrier Dysfunction in Alzheimer’s Disease: New Mechanistic Insights and Therapeutic Strategies | 000 | 2 | NIH | 1/27/2026 | $641,933 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG093847 | Lactate as a regulator of Alzheimer's pathology | 000 | 2 | NIH | 3/9/2026 | $747,968 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AI155545 | Anti-inflammatory functions for non-transcriptional IRF3 | 000 | 5 | NIH | 1/30/2026 | $420,465 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG080589 | APOE Allele Switching as a Therapeutic Approach for Alzheimer's Disease | 000 | 4 | NIH | 12/10/2025 | $578,038 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG080589 | APOE Allele Switching as a Therapeutic Approach for Alzheimer's Disease | 001 | 4 | NIH | 2/23/2026 | $64,226 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082142 | MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | 001 | 4 | NIH | 2/23/2026 | $65,188 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 001 | 3 | NIH | 2/26/2026 | $65,020 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 000 | 3 | NIH | 1/19/2026 | $585,180 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG082142 | MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | 000 | 4 | NIH | 12/22/2025 | $586,701 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG081608 | Molecular Genetics of Human Age-Related Hearing Loss | 001 | 4 | NIH | 3/10/2026 | $587,270 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R37CA278989 | Mechanistic and structural insights into a new pro-metastatic collagen glucosyltransferase | 000 | 3 | NIH | 2/6/2026 | $451,399 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM156952 | Gene regulatory network plasticity in social behavior | 001 | 2 | NIH | 3/11/2026 | $36,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM156952 | Gene regulatory network plasticity in social behavior | 000 | 2 | NIH | 1/16/2026 | $328,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35HL150818 | Platelet Exocytosis and Endocytosis in Thrombosis and Immunity | 000 | 7 | NIH | 3/2/2026 | $884,606 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25ES027684 | Summer Research in Environmental Health Sciences | 000 | 9 | NIH | 2/6/2026 | $133,879 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R33DC019602 | Hearing Healthcare Assessment in Rural Communities (HHARC) | 001 | 5 | NIH | 2/11/2026 | $473,067 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM131807 | Hedgehog Signaling in Development and Metabolism | 001 | 7 | NIH | 3/11/2026 | $41,580 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM130349 | Functional Analysis of Programmed Genome Rearrangement | 000 | 7 | NIH | 2/12/2026 | $430,737 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM131807 | Hedgehog Signaling in Development and Metabolism | 000 | 7 | NIH | 1/23/2026 | $374,220 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21HD117520 | Evaluating causes for failure to thrive in a Noonan-like syndrome with loose anagen hair (NSLH) patients using NSLH vertebrate model | 000 | 2 | NIH | 12/2/2025 | $173,250 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS147149 | Repetitive Mild TBI and Physiological Stress as Catalysts for Chronic Neurovascular Dysfunction | 000 | 1 | NIH | 1/26/2026 | $192,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098189 | Decoding the Muscle Epitranscriptome: Deep Learning Detection of RNA Modifications in Aging Muscle | 000 | 1 | NIH | 1/21/2026 | $616,000 |
|
